AMP Capital Investors Ltd lifted its position in C.R. Bard, Inc. (NYSE:BCR) by 8.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,818 shares of the medical instruments supplier’s stock after acquiring an additional 1,595 shares during the period. AMP Capital Investors Ltd’s holdings in C.R. Bard were worth $6,352,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Alps Advisors Inc. raised its position in shares of C.R. Bard by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock worth $607,000 after acquiring an additional 5 shares in the last quarter. KCM Investment Advisors LLC increased its position in C.R. Bard by 0.5% during the 2nd quarter. KCM Investment Advisors LLC now owns 2,187 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 10 shares in the last quarter. Parallel Advisors LLC increased its position in C.R. Bard by 2.8% during the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after buying an additional 14 shares in the last quarter. Montag A & Associates Inc. increased its position in C.R. Bard by 3.9% during the 2nd quarter. Montag A & Associates Inc. now owns 2,125 shares of the medical instruments supplier’s stock valued at $672,000 after buying an additional 80 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its position in C.R. Bard by 7.8% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,375 shares of the medical instruments supplier’s stock valued at $441,000 after buying an additional 100 shares in the last quarter. 79.35% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts recently weighed in on the company. ValuEngine lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Barclays raised their price objective on C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research report on Monday, November 6th. Jefferies Group reaffirmed a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Thursday, September 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. Finally, Cowen reaffirmed a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a strong buy rating to the stock. C.R. Bard presently has an average rating of “Hold” and a consensus target price of $303.50.

In other C.R. Bard news, insider Sharon M. Luboff sold 30,252 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $320.00, for a total transaction of $9,680,640.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Timothy P. Collins sold 8,388 shares of the stock in a transaction on Monday, October 9th. The shares were sold at an average price of $322.00, for a total value of $2,700,936.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 206,637 shares of company stock worth $67,650,121. Company insiders own 0.80% of the company’s stock.

Shares of C.R. Bard, Inc. (NYSE:BCR) opened at $332.00 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. C.R. Bard, Inc. has a 52 week low of $216.55 and a 52 week high of $337.73. The company has a market capitalization of $24,206.82, a price-to-earnings ratio of 28.68, a price-to-earnings-growth ratio of 2.54 and a beta of 0.52.

C.R. Bard (NYSE:BCR) last issued its earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the consensus estimate of $2.96 by $0.06. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The business had revenue of $989.80 million for the quarter, compared to the consensus estimate of $990.64 million. During the same period last year, the business posted $2.64 EPS. The company’s revenue was up 5.1% compared to the same quarter last year. equities research analysts anticipate that C.R. Bard, Inc. will post 11.89 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be paid a dividend of $0.26 per share. The ex-dividend date is Thursday, December 7th. This represents a $1.04 annualized dividend and a yield of 0.31%. C.R. Bard’s dividend payout ratio is 13.70%.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/amp-capital-investors-ltd-increases-stake-in-c-r-bard-inc-bcr/1763108.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.